Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–11 of 11 results
Advanced filters: Author: Axel Bex Clear advanced filters

  • Venous tumour thrombus can occur within renal cell carcinoma, and can require complex additional surgery and treatment. Here, the authors analyse multiparametric data from patients treated with axitinib and develop a machine learning model to predict neoadjuvant treatment response.

    • Rebecca Wray
    • Hania Paverd
    • Robert J. Jones
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-14

  • CARMENA, a trial comparing the efficacy of sunitinib alone to that of nephrectomy followed by sunitinib in patients with primary metastatic renal cell carcinoma who require targeted therapy has demonstrated the non-inferiority of systemic therapy alone. The data provided by this and other studies argue for a lesser role of surgery in the management of these patients.

    • Axel Bex
    • John Haanen
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 15, P: 595-596

  • Cytoreductive nephrectomy is the current treatment paradigm for metastatic renal cell carcinoma (RCC). However, the introduction of targeted therapies has dramatically changed the treatment landscape and may limit the role of nephrectomy in this disease. The recent CARMENA trial supports initial medical treatment of patients with RCC and synchronous metastases.

    • Viktor Grünwald
    • Axel Bex
    News & Views
    Nature Reviews Nephrology
    Volume: 14, P: 601-602

  • Although immune checkpoint inhibitors can prolong survival in people with clear-cell renal-cell carcinoma, disease progression is frequent. Here, the authors explore potential mechanisms that might drive intrinsic or acquired resistance to immune checkpoint inhibitors in clear-cell renal-cell carcinoma, including malignant cell-intrinsic and immune-cell factors.

    • Femke H. Burgers
    • Johannes C. K. van der Mijn
    • John B. A. G. Haanen
    Reviews
    Nature Reviews Nephrology
    Volume: 21, P: 687-701

  • Tumours can require certain amino acids for their proliferation, and the diricore method described here helps to identify such restrictive amino acids; using this method in kidney cancer tissue and breast carcinoma cells, the authors observe an association between proline deficiency and upregulation of PYCR1, an enzyme required for proline synthesis.

    • Fabricio Loayza-Puch
    • Koos Rooijers
    • Reuven Agami
    Research
    Nature
    Volume: 530, P: 490-494

  • In this Review, the authors discuss advantages and complications associated with renal mass biopsy and provide an overview of different features of both well-recognized types of renal cell carcinoma and newly identified subtypes to improve diagnosis and management.

    • Hussein Mansour
    • My-Anh Tran-Dang
    • Soha El Sheikh
    Reviews
    Nature Reviews Urology
    Volume: 22, P: 8-25

  • Effective adjuvant therapies are needed to reduce the risk of recurrence of kidney cancer. Here, the authors discuss the results of adjuvant therapy trials, the potential of immune checkpoint inhibitors as adjuvant therapies and the need for multidisciplinary management of patients with resected kidney cancer.

    • Camillo Porta
    • Laura Cosmai
    • Axel Bex
    Reviews
    Nature Reviews Nephrology
    Volume: 15, P: 423-433

  • In this Review, the authors provide an overview of currently available diagnostic liquid biopsy biomarkers for renal cell carcinoma, comparing clinical potential and limitations of the three most promising liquid biomarkers: circulating tumour cells, extracellular vesicles and cell-free DNA.

    • Richard C. Zieren
    • Patricia J. Zondervan
    • Adriaan D. Bins
    Reviews
    Nature Reviews Urology
    Volume: 21, P: 133-157

  • In this Expert Consensus, Grünwald et al. summarize their recommendations for the diagnosis and treatment of patients with renal cell carcinoma and metastasis to the bone. They also outline current challenges and unmet patient needs that should be addressed in the future.

    • Viktor Grünwald
    • Berit Eberhardt
    • Michael Staehler
    ReviewsOpen Access
    Nature Reviews Urology
    Volume: 15, P: 511-521